Balkhi et al. (Balkhi et al. 2006) recently showed that AML from various cytogenetic risk groups, healthy bone marrow and CD34+ cells, could be distinguished based on protein expression and mass spectrometry (MS) peak patterns corresponding to post-translational modification differences. Here, CD34 is linked to acute myeloid leukemia.